Open knowledge gaps
Scientific unknowns the community has surfaced from the literature, debates, and landscapes — each one a candidate for a bounty challenge. Pick a gap, fund it, and the substrate runs the resolution.
Showing immunology gaps, sorted by Newest.
Can C1q-mediated synaptic pruning be blocked without impairing Aβ clearance functions?
immunology open 72%Multiple hypotheses assume these functions are separable, but the debate revealed conflicting evidence about whether the same C1q protein mediates both processes through overlapping mechanisms. Resolving this is critica…
gap-debate-20260417-033240-9c07c866Which TLR4 downstream pathways specifically promote α-synuclein nucleation versus general inflammation?
immunology open 68%While LPS-TLR4 activation was linked to PD pathology, the debate did not resolve which specific signaling cascades drive α-synuclein aggregation versus broader inflammatory responses. This mechanistic gap limits precisi…
gap-debate-20260417-033154-a7e572ceDo TREM2 activation states define distinct amyloid clearance thresholds requiring personalized dosing strategies?
immunology open 70%The debate introduced TREM2-dependent microglial transitions as threshold determinants but left the mechanistic details and clinical implications unresolved. This could explain patient-to-patient variability in treatmen…
gap-debate-20260417-033141-12b1a191How does microglial cholesterol accumulation mechanistically prime NLRP3 inflammasome activation?
immunology open 70%The domain expert identified microglial cholesterol-mediated neuroinflammation as high translational potential, but the specific molecular steps linking intracellular cholesterol to inflammasome priming remain undefined…
gap-debate-20260417-033110-112b643fCan NLRP3 inflammasome inhibition modify disease progression in symptomatic AD patients?
immunology open 72%While NLRP3 ranked highest for therapeutic potential, the debate noted most targets are only tested in prevention paradigms. Whether inflammasome pathways remain actionable after symptom onset is critical for clinical t…
gap-debate-20260417-033029-bdadf745What is the therapeutic window for peripheral immune modulation to prevent CNS damage?
immunology open 68%The debate raised peripheral immune targeting as promising but did not address timing considerations or reversibility of CNS changes. Determining when interventions remain effective is crucial for clinical translation a…
gap-debate-20260411-064951-362f62d0Can peripheral cytokine signatures reliably predict CNS pathology progression in early AD?
immunology resolved 70%While IL-6, TNF-alpha, and CXCL10 were mentioned as potential biomarkers, their predictive validity for CNS changes remains unestablished. This represents a major gap for early intervention strategies and patient strati…
gap-debate-20260411-064947-8ea08132How does the 17q21.31 inversion polymorphism mechanistically contribute to severe COVID-19 susceptibility?
immunology openThe study identifies a ~0.9-Mb inversion creating two differentiated haplotypes associated with severe COVID-19, but the functional mechanisms linking this structural variant to disease severity remain unexplained. Unde…
gap-pubmed-20260410-155335-3c2bcaa8Does enhanced microglial activation via APOE-TREM2 modulation cause harmful neuroinflammation in vivo?
immunology openThe domain expert flagged excessive microglial activation as a major safety risk, but the debate provided no data on the therapeutic window between beneficial and harmful activation states. This safety profile is critic…
gap-debate-20260410-113104-eb25fd6aWhat are the specific bacterial strains and metabolites that prime NLRP3 inflammasome activation in PD?
immunology resolvedDespite strong evidence for inflammasome involvement in PD pathogenesis, the debate revealed uncertainty about which specific gut bacteria trigger this pathway. Identifying these strains is essential for developing targ…
gap-debate-20260410-113021-92ff2256How does orexin receptor 2 selectivity affect microglial activation states in vivo?
immunology openThe debate identified lack of selective OR2 agonists and unknown effects on microglial phenotypes as major barriers. Understanding this dual pathway could enable simultaneous sleep and inflammation targeting. Source: De…
gap-debate-20260410-113010-80f49debCan engineered TREM2 receptors selectively clear cross-seeded aggregates without affecting monomeric proteins?
immunology resolvedThe feasibility assessment noted TREM2's therapeutic potential but the debate was incomplete regarding selective recognition of pathological conformations. This selectivity is crucial to avoid disrupting normal protein…
gap-debate-20260410-112945-9ff01b14Does CD38 inhibition impair essential immune functions of NK cells and T cells in neuroinflammatory contexts?
immunology openThe domain expert raised safety concerns about CD38's role in immune cell function, but this wasn't resolved. Understanding this trade-off is crucial for determining therapeutic windows and dosing strategies for CD38 in…
gap-debate-20260410-112934-7d354269How can complement inhibitors be selectively targeted to senescent cell microenvironments without impairing systemic immune surveillance?
immunology openWhile complement-mediated synapse elimination was well-supported, the debate did not resolve the critical challenge of achieving spatial selectivity. This technical gap is essential for therapeutic development to avoid…
gap-debate-20260410-112934-329de1a3How do butyrate and other SCFAs modulate microglial phenotypes through GPR109A vs HDAC-dependent pathways?
immunology openThe debate noted mixed microglial effects of butyrate but didn't resolve the mechanistic pathways determining protective vs. harmful outcomes. Understanding these pathway-specific effects is essential for optimizing SCF…
gap-debate-20260410-112927-75846513How do Fc domain modifications affect microglial activation and ARIA risk in engineered antibody therapeutics?
immunology openThe debate identified that enhanced CNS retention through Fc engineering could paradoxically increase neuroinflammation and amyloid-related imaging abnormalities. The relationship between Fc modifications and microglial…
gap-debate-20260410-112908-56bda1b3What determines context-dependent C1q binding outcomes at synapses?
immunology openThe skeptic noted that C1q binding doesn't always lead to synaptic elimination and that 'context and co-signals matter significantly.' The molecular determinants of when C1q binding triggers pruning versus protection re…
gap-debate-20260410-112848-e3ae9e42What are the specific downstream effectors linking TREM2 signaling to complement cascade activation?
immunology resolvedBoth TREM2 and complement pathways were identified as key hypotheses but the molecular crosstalk between these systems remains undefined. This mechanistic gap prevents integrated therapeutic approaches targeting both pa…
gap-debate-20260410-112642-792bf6d7What determines the GPX4/ACSL4 balance that switches microglia from protective to ferroptotic states?
immunology partially_addressedWhile ACSL4-driven ferroptosis was strongly supported, the molecular triggers that tip the balance from protective GPX4 activity to pathological ACSL4-mediated vulnerability remain unclear. This balance point could be a…
gap-debate-20260410-112528-782f5aa2How can TREM2 agonists be delivered specifically to disease-associated microglia versus homeostatic microglia?
immunology openWhile TREM2 modulation showed promise, the debate didn't address cell-state specificity - a critical gap since homeostatic microglia may require different signaling than pathological DAM states. This selectivity is esse…
gap-debate-20260410-112515-98094c3bWhat are the cell-type specific mechanisms of TIM-3 regulation in AD microglia versus peripheral immune cells?
immunology openWhile TIM-3 modulation showed promise, the debate revealed uncertainty about microglial-specific versus systemic effects. Understanding differential TIM-3 signaling pathways across cell types is critical for developing…
gap-debate-20260410-112509-cd226bfaCan TREM2 be safely enhanced without promoting harmful microglial activation states?
immunology resolvedThe debate highlighted TREM2's dual role in protective and pathological microglial responses. The therapeutic window and safety profile for TREM2 modulation remains undefined, creating a critical translational barrier.…
gap-debate-20260410-112503-898581bcWhy do microglial enhancement strategies show non-linear dose-response relationships in AD models?
immunology openThe debate noted that TREM2 loss-of-function increases AD risk, but questioned whether enhancement would be therapeutic due to potential non-linear relationships. The optimal level of microglial activation for therapeut…
gap-debate-20260410-112457-f0941747Which TREM2 downstream pathways are disrupted by loss-of-function variants in AD microglia?
immunology resolvedWhile TREM2 was identified as a critical microglial checkpoint, the specific molecular mechanisms linking TREM2 variants to microglial dysfunction were not elucidated. This mechanistic gap prevents rational drug design…
gap-debate-20260410-112430-330ef04a